Xilio Therapeutics, Inc.
Total Trades
13
Buys
3
Sells
6
Largest Trade
N/A
Insiders
6
Institutional Funds
25
Inst. Value
$1M+
Activist Filings
29
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Brennan Kevin M. | SVP | EXERCISE | N/A | 5K | — | Jan 5, 2026 |
| Brennan Kevin M. | SVP | SELL | $1K–$15K | 2K | $0.64 | Jan 5, 2026 |
| Frankenfield Christopher James | CFO | SELL | $1K–$15K | 7K | $0.64 | Jan 5, 2026 |
| Frankenfield Christopher James | CFO | EXERCISE | N/A | 19K | — | Jan 5, 2026 |
| Shannon James Samuel | Director | BUY | $15K–$50K | 70K | $0.69 | Jun 18, 2025 |
| Russo Rene | PRESIDENT AND CEO | BUY | $15K–$50K | 36K | $0.68 | Jun 18, 2025 |
| Frankenfield Christopher James | CFO | SELL | $1K–$15K | 7K | $0.98 | Jan 3, 2025 |
| Frankenfield Christopher James | CFO | EXERCISE | N/A | 19K | — | Jan 3, 2025 |
| Brennan Kevin M. | SVP | SELL | $1K–$15K | 2K | $0.98 | Jan 3, 2025 |
| Brennan Kevin M. | SVP | EXERCISE | N/A | 5K | — | Jan 3, 2025 |
| GILEAD SCIENCES, INC. | 10% Owner | BUY | $100K–$500K | 485K | $0.76 | Apr 3, 2024 |
| Atlas Venture Fund XI, L.P. | 10% Owner | SELL | <$1K | 1K | $0.64 | Feb 9, 2024 |
| Atlas Venture Fund XI, L.P. | 10% Owner | SELL | $1K–$15K | 4K | $0.85 | Jan 16, 2024 |
Institutional Ownership
13F filings as of Dec 31, 2025 · 25 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| GILEAD SCIENCES, INC. | 9.1M | $1M+ | SH |
| Bain Capital Life Sciences Investors, LLC | 7.4M | $1M+ | SH |
| Frazier Life Sciences Management, L.P. | 5.9M | $1M+ | SH |
| Point72 Asset Management, L.P. | 4.0M | $1M+ | SH |
| Empery Asset Management, LP | 1.2M | $500K+ | SH |
| VANGUARD GROUP INC | 1.1M | $500K+ | SH |
| MORGAN STANLEY | 840K | $500K+ | SH |
| AJU IB Investment Co., Ltd. | 668K | $100K–$500K | SH |
| RENAISSANCE TECHNOLOGIES LLC | 344K | $100K–$500K | SH |
| GEODE CAPITAL MANAGEMENT, LLC | 270K | $100K–$500K | SH |
| STATE STREET CORP | 186K | $100K–$500K | SH |
| Velan Capital Investment Management LP | 170K | $100K–$500K | SH |
| GSA CAPITAL PARTNERS LLP | 148K | $50K–$100K | SH |
| Stonepine Capital Management, LLC | 126K | $50K–$100K | SH |
| HRT FINANCIAL LP | 32K | $15K–$50K | SH |
| Mariner, LLC | 25K | $15K–$50K | SH |
| LPL Financial LLC | 21K | $1K–$15K | SH |
| JANE STREET GROUP, LLC | 21K | $1K–$15K | SH |
| Dunhill Financial, LLC | 10K | $1K–$15K | SH |
| Pinnacle Financial Group, LLC / IL | 10K | $1K–$15K | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
Frazier Life Sciences Public Fund, L.P.
SC 13G/A · Feb 13, 2026
6.7%
4.7M shares
SC 13G/A · Feb 12, 2026
19.9%
14.5M shares
SC 13G · Dec 11, 2025
10.0%
5.3M shares
Point72 Asset Management, L.P.
SC 13G/A · Nov 14, 2025
9.9%
8.0M shares
SC 13G · Nov 14, 2025
7.2%
4.0M shares
SC 13G/A · Aug 14, 2025
19.9%
10.6M shares
Frazier Life Sciences Public Fund, L.P.
SC 13G/A · Aug 14, 2025
9.9%
8.1M shares
Point72 Asset Management, L.P.
SC 13G · Jun 17, 2025
7.2%
4.0M shares
Frazier Life Sciences Public Fund, L.P.
SC 13G · Jun 12, 2025
6.3%
3.5M shares
Rock Springs Capital Management LP
SC 13G/A · May 15, 2025
0.0%
0 shares
SC 13G · Feb 18, 2025
9.0%
4.3M shares
SC 13G/A · Dec 19, 2024
19.9%
9.1M shares
Bain Capital Life Sciences Fund II, L.P. 2
SC 13G/A · Nov 14, 2024
10.0%
4.6M shares
SC 13G/A · Nov 14, 2024
0.0%
0 shares
Rock Springs Capital Management LP
SC 13G/A · Nov 12, 2024
6.8%
3.0M shares
SC 13G/A · Nov 12, 2024
3.2%
1.4M shares
SC 13G · Sep 28, 2024
15.9%
7.0M shares
Takeda Pharmaceutical Company Limited
SC 13G/A · Jul 31, 2024
4.0%
1.5M shares
SC 13G · Apr 5, 2024
19.9%
7.3M shares
Rock Springs Capital Management LP
SC 13G/A · Apr 5, 2024
8.7%
3.0M shares
Rock Springs Capital Management LP
SC 13G · Feb 14, 2024
5.2%
1.4M shares
SC 13G · Apr 10, 2023
5.4%
1.5M shares
SC 13G · Jan 25, 2023
8.8%
2.4M shares
SC 13G/A · Dec 29, 2022
0.0%
0 shares
SC 13G/A · Nov 14, 2022
0.0%
0 shares
SC 13G/A · Feb 14, 2022
7.3%
2.0M shares
Bain Capital Life Sciences Fund II, L.P.
SC 13G/A · Feb 14, 2022
4.9%
1.3M shares
SC 13G/A · Feb 11, 2022
3.7%
1.0M shares
Takeda Pharmaceutical Company Limited
SC 13G · Jan 14, 2022
5.4%
1.5M shares